BRIEF REPORT

Epigenetic silencing of lncRNA *MORT* in 16 TCGA cancer types

[version 1; peer review: 3 approved]

Lukas Vrba ¹, Bernard W. Futscher^{1,2}

¹The University of Arizona Cancer Center, Tucson, AZ, 85724, USA

²Department of Pharmacology & Toxicology, College of Pharmacy, The University of Arizona, Tucson, AZ, 85724, USA

V1 First published: 21 Feb 2018, 7:211
<https://doi.org/10.12688/f1000research.13944.1>

Latest published: 21 Feb 2018, 7:211
<https://doi.org/10.12688/f1000research.13944.1>

Abstract

We have previously described a hominid-specific long non-coding RNA, *MORT* (also known as *ZNF667-AS1*, Gene ID: 100128252), which is expressed in all normal cell types, but epigenetically silenced during cancer-associated immortalization of human mammary epithelial cells. Initial analysis of The Cancer Genome Atlas (TCGA) showed that 15 of 17 cancer types, which represent the 10 most common cancers in women and men, display DNA methylation associated *MORT* silencing in a large fraction of their tumors. In this study we analyzed *MORT* expression and DNA methylation state in the remaining 16 TCGA cancer types not previously reported. Seven of the 16 cancer types showed DNA methylation linked *MORT* silencing in a large fraction of their tumors. These are carcinomas (cervical cancer, and cancers of esophagus, stomach, and bile duct), and the non-epithelial tumors mesothelioma, sarcoma, and uterine carcinosarcoma. Together with the findings from our previous report, *MORT* expression is silenced by aberrant DNA methylation in 22 of 33 of TCGA cancer types. These 22 cancers include most carcinoma types, blood derived cancers and sarcomas. In conclusion, results suggest that the *MORT* gene is one of the most common epigenetic aberrations seen in human cancer. Coupled with the timing of *MORT* gene silencing during *in vitro* epithelial cell immortalization and its occurrence early in the temporal arc of human carcinogenesis, this provides strong circumstantial evidence for a tumor suppressor role for *MORT*.

Keywords

DNA Methylation, Gene Silencing, lncRNA, ncRNA, lincRNA, *MORT*, *ZNF667-AS1*, Epigenetics

Open Peer Review

Approval Status

	1	2	3
version 1
21 Feb 2018	view	view	view

1. Adam Karpf , University of Nebraska Medical Center, Omaha, USA
2. Gwen Lomberk, Medical College of Wisconsin, Milwaukee, USA
3. Alexander Dobrovic , Olivia Newton-John Cancer Research Institute, Heidelberg, Australia

Any reports and responses or comments on the article can be found at the end of the article.

Corresponding author: Lukas Vrba (lvrba@uacc.arizona.edu)

Author roles: **Vrba L:** Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Software, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Futscher BW:** Funding Acquisition, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: This work was supported by the Maynard Chair in Breast Cancer Epigenomics at the University of Arizona Cancer Center and the Cancer Center Support Grant (P30 CA023074).

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2018 Vrba L and Futscher BW. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Vrba L and Futscher BW. **Epigenetic silencing of lncRNA *MORT* in 16 TCGA cancer types [version 1; peer review: 3 approved]** F1000Research 2018, 7:211 <https://doi.org/10.12688/f1000research.13944.1>

First published: 21 Feb 2018, 7:211 <https://doi.org/10.12688/f1000research.13944.1>

Introduction

MORT was originally found as a transcript silenced during *in vitro* immortalization of human mammary epithelial cells¹. Like a significant majority of lncRNAs, *MORT*'s molecular function remains enigmatic. The *MORT* gene is specific to higher primates, is expressed in all normal human cell types, and *MORT* RNA is located predominantly in the cytoplasm¹. Analysis of *MORT* expression and the DNA methylation state of its promoter in 17 cancer types from The Cancer Genome Atlas (TCGA)², which represent the 10 most frequent cancers in males and females, showed *MORT* is epigenetically silenced in 15 of 17 these cancers¹. Based on the data from the original *in vitro* study¹, we predicted epigenetic *MORT* silencing occurs early in human carcinogenesis and therefore could be seen in pre-malignant lesions, such as ductal carcinoma *in situ* of the breast and colonic adenomas. We used data from clinical samples from published genomic data sets^{3–8} to address this possibility, and indeed, *MORT* loss occurs prior to or at the stage of pre-malignancy and not thereafter⁹. Taken together these facts suggest that *MORT* transcript has a tumor suppressive role and is not simply an epigenetic “passenger error.”

Since our previous analysis of *MORT* in TCGA datasets was not exhaustive and only reported on 17 out of 33 TCGA cancer types, the goal of this short study was to extend our earlier work and complete the analysis of *MORT* DNA methylation associated gene silencing in the final 16 TCGA cancer types.

Methods

We integrated the *MORT* expression level and the DNA methylation state of its promoter region using TCGA data as described before¹. The Illumina HiSeq RNA-seq and HumanMethylation450 DNA methylation data for samples of 16 TCGA cancer types listed in Table 1 were downloaded from the GDC data portal. The data were analyzed in the R programming environment, version 3.4.2¹⁰. The mean RNA-Seq rpkm values for the two exons constituting the *MORT* RNA were plotted against the mean DNA methylation beta value of the 7 CpGs from the *MORT* promoter region for the individual samples of each cancer type. The Spearman correlation coefficient rho between the *MORT* RNA level and the DNA methylation of *MORT* promoter was calculated using the function cor.test.

Results and discussion

Seven of sixteen analyzed cancer types (CESC, CHOL, ESCA, MESO, SARC, STAD, and UCS) show strong *MORT* silencing by DNA methylation (Figure 1). The negative correlation rho between *MORT* expression and DNA methylation in these cancers is below -0.5; the DNA methylation level in some tumor samples of these cancers exceeds 0.5 beta (> 50% DNA methylation), and a large fraction of the tumor samples in these cancer types have very low to no *MORT* expression level (Figure 1). The correlation of *MORT* expression and promoter DNA methylation in the remaining nine cancer types is also negative; however, the maximum level of the DNA methylation

Table 1. The 16 TCGA cancer types analyzed in this study. The numbers of primary tumor and normal samples for which both the *MORT* RNA expression and the *MORT* promoter DNA methylation data were available are listed. *DNA methylation data from HumanMethylation27 platform that covers 2 CpGs out of 7 CpGs covered by HumanMethylation450 were used.

TCGA Cancer Type Name	Abbreviation	Tumor samples	Normal samples
adrenocortical carcinoma	ACC	79	0
cervical squamous cell carcinoma and endocervical adenocarcinoma	CESC	304	3
cholangiocarcinoma	CHOL	36	9
esophageal carcinoma	ESCA	184	9
glioblastoma multiforme	GBM	51	1
kidney chromophobe	KICH	66	0
brain lower grade glioma	LGG	516	0
mesothelioma	MESO	87	0
ovarian serous cystadenocarcinoma	OV*	295	0
pheochromocytoma and paraganglioma	PCPG	179	3
sarcoma	SARC	259	0
stomach adenocarcinoma	STAD	373	0
testicular germ cell tumors	TGCT	150	0
thymoma	THYM	120	2
uterine carcinosarcoma	UCS	57	0
uvea melanoma	UVM	80	0

Figure 1. Integration of the *MORT* expression and the *MORT* promoter DNA methylation TCGA data for 16 tumor types. The x-axis shows the *MORT* expression level according to RNA-seq and y-axis shows the level of *MORT* promoter DNA methylation according to Illumina HumanMethylation450 microarray. The correlation coefficient ρ between the *MORT* expression and the DNA methylation of *MORT* promoter for each tumor type is displayed. The OV has a very low number (10) of samples analyzed by the HumanMethylation450 platform, therefore the data from the HumanMethylation27 platform that covers 2 CpGs out of 7 CpGs covered by HumanMethylation450 were used.

of *MORT* promoter in some of these cancers is either very low (UVM), or a very few tumor samples have *MORT* silenced (ACC, KICH, OV, and THYM), and some of the cancer types (GBM, LGG, PCPG, and TGCT) do not appear to display *MORT* gene silencing (Figure 1).

The analysis presented shows DNA methylation associated *MORT* gene silencing in 7 of 16 TCGA cancer types. Compared to the 17 TCGA cancer types presented in our original study,¹ most the 16 cancer types presented here lack their respective normal tissues samples and some of them have lower amounts of tumor samples (Table 1). Nevertheless, the distribution of *MORT* expression and DNA methylation data in tumor samples clearly indicates *MORT* silencing in multiple cancer types (Figure 1).

Cervical tumors (CESC) have high proportion of *MORT* silencing (Figure 1); more than 75% of 304 cervical tumor samples have *MORT* promoter DNA hypermethylated and *MORT* silenced. Using TCGA data, a recent study found *MORT* downregulated in cervical cancer¹¹, but surprisingly did not report on or hypothesize potential mechanisms for this transcriptional repression. Here we confirm and extend their initial analysis of *MORT* silencing in cervical cancer and show further that this silencing is strongly linked to aberrant DNA methylation of the *MORT* promoter.

Combined together with the findings from our previous report¹, Table 2 shows *MORT* is silenced by DNA methylation in

Table 2. Summary of *MORT* silencing in all 33 TCGA cancer types. The cancer types with *MORT* silencing in a large fraction of tumor samples are indicated. Results from this study are indicated (*), results from our previous report (ref 1) are indicated (**).

Abbreviation	TCGA cancer type name	<i>MORT</i> silencing
ACC	adrenocortical carcinoma	No*
BLCA	bladder urothelial carcinoma	Yes**
BRCA	breast invasive carcinoma	Yes**
CESC	cervical squamous cell carcinoma and endocervical adenocarcinoma	Yes*
CHOL	cholangiocarcinoma	Yes*
COAD	colon adenocarcinoma	Yes**
DLBC	lymphoid neoplasm diffuse large b-cell lymphoma	Yes**
ESCA	esophageal carcinoma	Yes*
GBM	glioblastoma multiforme	No*
HNSC	head and neck squamous cell carcinoma	Yes**
KICH	kidney chromophobe	No*

Abbreviation	TCGA cancer type name	<i>MORT</i> silencing
KIRC	kidney renal clear cell carcinoma	Yes**
KIRP	kidney renal papillary cell carcinoma	Yes**
LAML	acute myeloid leukemia	Yes**
LGG	brain lower grade glioma	No*
LIHC	liver hepatocellular carcinoma	Yes**
LUAD	lung adenocarcinoma	Yes**
LUSC	lung squamous cell carcinoma	Yes**
MESO	mesothelioma	Yes*
OV	ovarian serous cystadenocarcinoma	No*
PAAD	pancreatic adenocarcinoma	Yes**
PCPG	pheochromocytoma and paraganglioma	No*
PRAD	prostate adenocarcinoma	No**
READ	rectum adenocarcinoma	Yes**
SARC	sarcoma	Yes*
SKCM	skin cutaneous melanoma	Yes**
STAD	stomach adenocarcinoma	Yes*
TGCT	testicular germ cell tumors	No*
THCA	thyroid carcinoma	No**
THYM	thymoma	No*
UCEC	uterine corpus endometrial carcinoma	Yes**
UCS	uterine carcinosarcoma	Yes*
UVM	uveal melanoma	No*

a super majority of TCGA cancer types (22 of 33). *MORT* loss occurs predominantly due to epigenetic silencing and increased DNA methylation of its promoter in breast cancer⁹. This could likely be extended to all 22 cancer types with the high fraction of *MORT* negative samples and the high correlation between *MORT* RNA level and *MORT* promoter DNA methylation, where *MORT* likely plays a tumor suppressive role. The other 11 cancer types, with a little to no *MORT* silencing, might have tumor suppressive pathway, where *MORT* is involved, interrupted elsewhere and/or *MORT* may play some additional vital role in tissues these tumors originate from - e.g. prostate, thyroid, brain, testes, or ovary - since these tissues typically have the highest levels of *MORT* RNA¹.

In summary, our findings show that the *MORT* gene is one of the most common epigenetic aberrations seen in human cancer. Coupled together with *MORT* silencing occurring early in the

temporal arc of human carcinogenesis it strongly supports a tumor suppressive role for *MORT*.

Data availability

Illumina HiSeq RNA-seq and HumanMethylation450 DNA methylation data for TCGA cancer types used in the present study can be downloaded from the [GDC data portal](#).

Competing interests

No competing interests were disclosed.

Grant information

This work was supported by the Maynard Chair in Breast Cancer Epigenomics at the University of Arizona Cancer Center and the Cancer Center Support Grant (P30 CA023074).

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Acknowledgments

The results shown here are based upon data generated by the TCGA Research Network: <http://cancergenome.nih.gov/>.

References

1. Vrba L, Garbe JC, Stampfer MR, *et al.*: **A lincRNA connected to cell mortality and epigenetically-silenced in most common human cancers.** *Epigenetics*. 2015; **10**(11): 1074–83.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
2. NCI, NHGRI, NIH: **The Cancer Genome Atlas.** NIH, National Cancer Institute, National Human Genome Research Institute, 2016.
[Reference Source](#)
3. Abba MC, Gong T, Lu Y, *et al.*: **A Molecular Portrait of High-Grade Ductal Carcinoma In Situ.** *Cancer Res*. 2015; **75**(18): 3980–90.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
4. Fleischer T, Frigessi A, Johnson KC, *et al.*: **Genome-wide DNA methylation profiles in progression to in situ and invasive carcinoma of the breast with impact on gene transcription and prognosis.** *Genome Biol*. 2014; **15**(8): 435.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
5. Johnson KC, Koestler DC, Fleischer T, *et al.*: **DNA methylation in ductal carcinoma in situ related with future development of invasive breast cancer.** *Clin Epigenetics*. 2015; **7**: 75.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
6. Luo Y, Wong CJ, Kaz AM, *et al.*: **Differences in DNA methylation signatures reveal multiple pathways of progression from adenoma to colorectal cancer.** *Gastroenterology*. 2014; **147**(2): 418–29.e8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
7. Qu X, Sandmann T, Frierson H Jr, *et al.*: **Integrated genomic analysis of colorectal cancer progression reveals activation of EGFR through demethylation of the EREG promoter.** *Oncogene*. 2016; **35**(50): 6403–6415.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
8. Reyngold M, Turcan S, Giri D, *et al.*: **Remodeling of the methylation landscape in breast cancer metastasis.** *PLoS One*. 2014; **9**(8): e103896.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
9. Vrba L, Futscher BW: **Epigenetic Silencing of MORT Is an Early Event in Cancer and Is Associated with Luminal, Receptor Positive Breast Tumor Subtypes.** *J Breast Cancer*. 2017; **20**(2): 198–202.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
10. Team RC: **R: A Language and Environment for Statistical Computing.** Vienna, Austria: R Foundation for Statistical Computing, 2017.
[Reference Source](#)
11. Zhao LP, Li RH, Han DM, *et al.*: **Independent prognostic Factor of low-expressed LncRNA ZNF667-AS1 for cervical cancer and inhibitory function on the proliferation of cervical cancer.** *Eur Rev Med Pharmacol Sci*. 2017; **21**(23): 5353–60.
[PubMed Abstract](#) | [Publisher Full Text](#)

Open Peer Review

Current Peer Review Status:

Version 1

Reviewer Report 03 April 2018

<https://doi.org/10.5256/f1000research.15158.r31592>

© 2018 Dobrovic A. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Alexander Dobrovic

Translational Genomics and Epigenomics Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia

This brief article provides an analysis of MORT epigenetic silencing across 16 TCGA tumour types not previously reported by the authors enabling assessment across all TCGA tumour types. MORT silencing seems to be a key early event in carcinogenesis. This indicates that further studies of MORT biology are required as well as investigation of MORT methylation as a potential biomarker.

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: DNA methylation biomarkers, liquid biopsies, digital PCR

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Reviewer Report 03 April 2018

<https://doi.org/10.5256/f1000research.15158.r31980>

© 2018 Lomberg G. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Gwen Lomberg

Division of Research, Department of Surgery, Medical College of Wisconsin, Milwaukee, WI, USA

STRENGTHS: The authors utilize the TCGA database to extend their previous studies on MORT that has been primarily characterized in breast cancer, but also observed to undergo silencing in 15 out of the 17 most common cancers. The current work takes this analysis deeper into the 33 TCGA

cancer types and perform a more thorough analysis of the DNA methylation associated with the 16 cancer types evaluated here.

SUGGESTIONS FOR IMPROVEMENT:

-The authors make a bold statement that “the MORT gene is one of the most common epigenetic aberrations seen in human cancer”. This statement is not supported by the data presented. In order to make a statement of this level, the authors would have to provide comparisons to other documented genes that undergo a high frequency of epigenetic alteration.

-This statement becomes more difficult to make when considering that several of the tumors present do not have normal counterparts for comparison. We therefore do not know if those tissue types whether the DNA methylation is abnormal or typical for the tissue type.

-Authors should consider revising some of the scales on the graphs in Figure 1 to highlight the lack of methylation (for example, in testicular germ cell tumors). Similarly, the cutoff for methylation could be shown by a dotted line or similar feature.

-The location of methylation relative to the MORT gene would be informative. Of the tumor types that are methylated, are the same regions methylated across types?

-The authors should be cautious not to overstate their conclusions throughout the text since the conclusions are speculative without experiments to support their statements. Nevertheless, these correlations present interesting speculation and avenues for further investigations.

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Reviewer Report 01 March 2018

<https://doi.org/10.5256/f1000research.15158.r31096>

© 2018 Karpf A. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Adam Karpf

Eppley Institute and Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, USA

The authors present a straightforward study of DNA methylation and RNA expression of the lncRNA MORT in 16 TCGA cancer types not previously reported. Most of the paper is clearly presented and the conclusions are reasonable. Suggestions for improvement are presented below.

- 1) Statements are made regarding MORT being “one of the most common” epigenetic aberrations seen in human cancer. No support for this statement is presented.
- 2) The classification of some tumor types as showing “strong” MORT silencing by DNA methylation, and other tumor types as not showing this, is arbitrary. A quantitative definition is needed.
- 3) Fig 1 might be clearer if presented in two panels, subdivided by whether the quantitative definition of “strong silencing” is met. The same is true for Table 2, which could be subdivided into two parts.
- 4) Since normal samples were not available for many of the tumors profiled, a more accurate statement might be “DNA methylation regulation” rather than “DNA methylation silencing,” as reduced expression in tumors as compared to normal tissues was not shown.
- 5) A diagram showing the MORT gene and the position of the methylation sites examined by the TCGA would be helpful.
- 6) Can the authors reference any data, e.g. from other publications, showing that DNA methylation actively suppresses MORT expression, by for example turning on MORT expression using treatment with a DNA methyltransferase inhibitor?
- 7) In the introduction, the statement “prior to or at the stage of pre-malignancy and not thereafter” is confusing, and gives the impression that MORT becomes hypomethylated, or its expression is elevated, in tumors as compared to pre-malignant lesions. A better way to phrase this would be to say e.g. that “MORT is repressed in pre-malignant lesions and remains repressed in tumors.”
- 8) The final sentence in the discussion uses the wording “strongly supports” when “suggests” would be more accurate, given the absence of functional data showing tumor suppression by MORT.

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research